Search - tctmd.com

Displaying 1 - 20 of 88

Sort: Relevancy | Date

Good Results but Small Numbers With JenaValve Trilogy in Severe AR

News Conference News PCR London Valves 2021

Good Results but Small Numbers With JenaValve Trilogy in Severe AR

Michael O'Riordan

November 26, 2021

MitraClip Cuts HF Hospitalizations in Real-World Registry: EXPAND

News Conference News PCR London Valves 2021

MitraClip Cuts HF Hospitalizations in Real-World Registry: EXPAND

November 26, 2021

‘Reasonable’ Results With TMVR for Mitral Regurgitation: CHOICE-MI

News Conference News PCR London Valves 2021

‘Reasonable’ Results With TMVR for Mitral Regurgitation: CHOICE-MI

Michael O'Riordan

November 25, 2021

Promising Early Results for TriClip in Tricuspid Regurgitation: bRIGHT Registry

News Conference News PCR London Valves 2021

Promising Early Results for TriClip in Tricuspid Regurgitation: bRIGHT Registry

November 24, 2021

Risk-Based EHR Alert Doesn’t Improve HF Care or Outcomes: REVEAL-HF

News Conference News AHA 2021

Risk-Based EHR Alert Doesn’t Improve HF Care or Outcomes: REVEAL-HF

Michael O'Riordan

November 19, 2021

Empagliflozin Retains Benefits in ‘True’ HFpEF Patients

News Conference News AHA 2021

Empagliflozin Retains Benefits in ‘True’ HFpEF Patients

November 17, 2021

Trial of Cell Therapy for HF Misses Primary Endpoint, but Signals a Path Forward

News Conference News

Trial of Cell Therapy for HF Misses Primary Endpoint, but Signals a Path Forward

November 16, 2021

Canagliflozin Improves Quality of Life in HF Patients

News Conference News AHA 2021

Canagliflozin Improves Quality of Life in HF Patients

Michael O'Riordan

November 16, 2021

No Benefit for Icosapent Ethyl, P2Y12 Inhibitors in Separate COVID-19 Trials

News Conference News AHA 2021

No Benefit for Icosapent Ethyl, P2Y12 Inhibitors in Separate COVID-19 Trials

November 15, 2021

Empagliflozin Safe in Acute HF, Improves ‘Clinical Benefit’ Over Time

News Conference News AHA 2021

Empagliflozin Safe in Acute HF, Improves ‘Clinical Benefit’ Over Time: EMPULSE

November 14, 2021

Fitbit Joins the AF Hunt, but Effect on Treatment, Outcomes Unknown

News Conference News AHA 2021

Fitbit Joins the AF Hunt, but Effect on Treatment, Outcomes Unknown

Yael L. Maxwell

November 14, 2021

External Support for Vein Grafts in CABG Doesn’t Help Patency: VEST

News Conference News AHA 2021

External Support for Vein Grafts in CABG Doesn’t Help Patency: VEST

Yael L. Maxwell

November 14, 2021

Tricuspid Repair During Mitral Surgery Slows Disease Progression at 2 Years

News Conference News AHA 2021

Tricuspid Repair During Mitral Surgery Slows Disease Progression at 2 Years

November 13, 2021

News Conference News AHA 2021

AVATAR Supports Early SAVR in Asymptomatic Severe AS Patients

November 13, 2021

News Conference News TCT 2021

Debating ISCHEMIA: Do the Results Apply to CABG, Too?

Michael O'Riordan

November 10, 2021

Conservative Management, Careful Diagnosis Key for Good SCAD Outcomes

News Conference News TCT 2021

Conservative Management, Careful Diagnosis Key for Good SCAD Outcomes

Yael L. Maxwell

November 09, 2021

Transcatheter Mitral, Tricuspid Valve Replacement Inch Forward

News Conference News TCT 2021

Transcatheter Mitral, Tricuspid Valve Replacement Inch Forward

Yael L. Maxwell

November 06, 2021

GUIDE-HF Hints That Hemodynamic-Guided Management Works in HFpEF

News Conference News TCT 2021

GUIDE-HF Hints That Hemodynamic-Guided Management Works in HFpEF

Michael O'Riordan

November 06, 2021

More Complications With Plug Closure After TAVI: CHOICE-CLOSURE

News Conference News TCT 2021

More Complications With Plug Closure After TAVI: CHOICE-CLOSURE

Michael O'Riordan

November 05, 2021

TAVI Edges Out Surgery in 2-Year Costs for Low-risk Patients: PARTNER 3

News Conference News TCT 2021

TAVI Edges Out Surgery in 2-Year Costs for Low-risk Patients: PARTNER 3

Yael L. Maxwell

November 05, 2021

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.